Pacific Edge Launches NZ$25.4M Raise to Win Back US Medicare Coverage
Pacific Edge raises NZ$25.4 million to pursue Medicare re-coverage and bladder cancer diagnostics growth
Pacific Edge Limited (NZX/ASX: PEB) has completed a placement of new ordinary shares, raising NZ$25.4 million after the board resolved to increase the raise and accept oversubscriptions following strong investor demand. The placement was priced at NZ$0.17 per share, representing a 2.3% discount to the closing share price on 8 May 2026, and was completed on Tuesday, 12 May 2026.
A Retail Offer to eligible existing shareholders of up to NZ$6 million at the same NZ$0.17 offer price will follow, with oversubscriptions accepted at Pacific Edge’s discretion. The Retail Offer Document is scheduled for release on Thursday, 14 May 2026.
When big ASX news breaks, our subscribers know first
How the capital will be deployed
The proceeds from both the Placement and the Retail Offer are intended to support four strategic priorities:
- Supporting ongoing operations and growth
- Achieving Medicare re-coverage in the US
- Continuing evidence generation through Pacific Edge’s clinical evidence programme
- Product development and innovation
Medicare re-coverage represents the most immediate commercial catalyst. Without US Medicare reimbursement, test volumes in the company’s largest market remain constrained. Alongside this, Pacific Edge is actively working to expand acceptance among broader commercial payers in the US and internationally, which management characterises as the longer-term growth lever.
The raise is structured to provide sufficient runway for these milestones to be pursued, rather than as a response to operational difficulty.
Chairman Simon Flood
“We are delighted with the investor support we have received. The new capital will allow us to consolidate our market position in bladder cancer diagnostics. It will support the Company and its operations to regain Medicare coverage and assist our move towards the broader adoption of our tests by commercial payers in the US and further afield. We are determined not to lose that momentum.”
Chief Executive Dr Peter Meintjes
“The robust evidence emerging from our clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests with opportunities in the US and in the Asia Pacific Region. We are delighted with the strong support we have received from investors in the Placement to continue to pursue our plans, and we are looking forward to making the Retail Offer to eligible shareholders at the same offer price.”
Understanding Cxbladder and why Medicare re-coverage is the key milestone
Cxbladder is a suite of non-invasive genomic urine tests designed for bladder cancer risk stratification. In plain terms, these are urine-based tests that analyse genetic markers to help clinicians assess whether a patient is at risk of bladder cancer, either at the point of first presentation (when blood is detected in urine) or during ongoing monitoring for patients who have previously had the disease.
The tests are backed by over 20 years of research and more than 25 peer-reviewed publications. Cxbladder Triage has been included in the American Urological Association’s Microhematuria Guideline, a meaningful marker of clinical acceptance in the US market.
For investors, Medicare coverage is the central revenue lever. Medicare is the US federal health insurance programme for those aged 65 and over, a demographic with significant overlap with bladder cancer patients. Re-coverage would directly enable reimbursement for tests ordered by the more than 5,000 US urologists who have already used Cxbladder, with over 130,000 tests ordered to date. Geographically, the product is available across the US, Australasia, Israel, Asia, and South America, positioning it as a global platform with the US representing the primary near-term revenue focus.
| Metric | Detail |
|---|---|
| Research history | 20+ years |
| Peer-reviewed publications | 25+ |
| US urologists reached | 5,000+ |
| Tests ordered (US) | 130,000+ |
| Markets | US, Australasia, Israel, Asia, South America |
The next major ASX story will hit our subscribers first
Placement terms and retail offer: what investors need to know
The capital raise consists of two separate components. The Placement, directed at institutional and other investors, has been completed. The Retail Offer, directed at eligible existing shareholders, is forthcoming at the same price.
Key terms for both:
- Placement size: NZ$25.4 million (completed, with oversubscriptions accepted)
- Retail Offer size: Up to NZ$6 million (oversubscriptions at Pacific Edge’s discretion)
- Offer price (both): NZ$0.17 per share
- Discount: 2.3% to the 8 May 2026 closing price
The capital raise timeline is as follows:
- 8 May 2026 — Placement announced; announcement and presentation released to NZX/ASX on 11 May 2026
- 12 May 2026 — Placement completed
- 14 May 2026 — Retail Offer Document released and sent to eligible shareholders
Pacific Edge is advised on the raise by Cameron Partners (investment banking), Harmos Horton Lusk (legal), and The Project (investor relations and communications). Management’s stated intent is to maintain commercial momentum in bladder cancer diagnostics while pursuing Medicare re-coverage as its primary near-term objective.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Over 20,000+ subscribers already rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to get the next big healthcare update the moment it breaks.